Sugi Predict

Sugi Predict / Compounds / SCHEMBL390679

SCHEMBL390679

SCHEMBL390679

NC(c1ccc(Cl)cc1)C1CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADRB2 P07550 1/20 0.48
▸ OPRM1 P35372 3/20 0.47
▸ OPRD1 P41143 3/20 0.47
▸ OPRK1 P41145 3/20 0.47
▸ OPRL1 P41146 3/20 0.47
▸ AKT2 P31751 3/20 0.47
▸ GSK3B P49841 2/20 0.47
▸ RPS6KB1 P23443 1/20 0.43
▸ IDO1 P14902 1/20 0.40
▸ TDO2 P48775 1/20 0.40
▸ SLC6A4 P31645 5/20 0.40
▸ SLC6A2 P23975 3/20 0.40
▸ SLC6A3 Q01959 3/20 0.40
▸ TSHR P16473 2/20 0.39
▸ MAPK1 P28482 2/20 0.39
▸ HIF1A Q16665 2/20 0.39
▸ TDP1 Q9NUW8 2/20 0.39
▸ LMNA P02545 2/20 0.38
▸ TP53 P04637 1/20 0.38
▸ HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12574569 1.00 ADRB2 (0.48) ADRB2OPRM1OPRD1OPRK1OPRL1
SCHEMBL2677241 1.00 ADRB2 (0.48) ADRB2OPRM1OPRD1OPRK1OPRL1
SCHEMBL31091021 1.00 ADRB2 (0.48) ADRB2OPRM1OPRD1OPRK1OPRL1
Hydrochloric Acid SCHEMBL20474787 0.98 ADRB2 (0.46) ADRB2OPRM1OPRD1OPRK1OPRL1
Hydrochloric Acid SCHEMBL20474788 0.98 ADRB2 (0.46) ADRB2OPRM1OPRD1OPRK1OPRL1
SCHEMBL7456086 0.91 OPRM1 (0.45) ADRB2OPRM1OPRD1OPRK1OPRL1
SCHEMBL4064296 0.86 SLC6A4 (0.53) OPRM1OPRD1OPRK1OPRL1AKT2
Hydrochloric Acid SCHEMBL4069007 0.85 SLC6A4 (0.55) AKT2GSK3BSLC6A4SLC6A2SLC6A3
SCHEMBL16380668 0.83 AKT2 (0.49) ADRB2OPRM1OPRD1OPRK1OPRL1
SCHEMBL13591095 0.83 AKT2 (0.49) ADRB2OPRM1OPRD1OPRK1OPRL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12252495-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2025-03-18 — — US disclosed
EP-4352046-A1 ISOINDOLINONE COMPOUNDS, AND USES THEREOF Hangzhou Glubio Pharmaceutical Co., Ltd. (CN) 2024-04-17 — — EP disclosed
US-20240109902-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2024-04-04 — — US disclosed
US-11760760-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2023-09-19 — — US disclosed
US-11760760-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2023-09-19 — — US disclosed
US-11760760-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2023-09-19 — — US disclosed
WO-2022257897-A1 ISOINDOLINONE COMPOUNDS, AND USES THEREOF HANGZHOU GLUBIO PHARMACEUTICAL CO., LTD. (CN) 2022-12-15 — — WO disclosed
US-20220220116-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2022-07-14 — — US disclosed
US-20220220116-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2022-07-14 — — US disclosed
US-11236095-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2022-02-01 — — US disclosed
US-20030105098-A1 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines AVENTISUB II INC. 2003-06-05 — — US disclosed
US-6479487-B1 INHIBIT CYCLIN DEPENDENT KINASES, PARTICULARLY CDK-2; ANTIAPOPTOSIS AGENT; INHIBITS DEVELOPMENT OF NEOPLASMS AVENTIS PHARMACEUTICALS INC. 2002-11-12 — — US disclosed
EP-1056744-A1 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES Aventis Pharmaceuticals Inc. (US) 2000-12-06 — — EP disclosed
WO-2000012522-A1 MACROLIDE LHRH ANTAGONISTS ABBOTT LABORATORIES (US) 2000-03-09 — — WO disclosed
EP-0543402-B1 Aralkylaminopyrimidine derivative, method for preparing the same and composition for controlling noxious organisms UBE INDUSTRIES (JP) 2000-03-01 — — EP disclosed
US-6020521-A Macrolide LHRH antagonists ABBOTT LABORATORIES (US) 2000-02-01 — — US disclosed
WO-1999043675-A1 6,9-DISUBSTITUTED 2-[TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES AVENTIS PHARMACEUTICALS INC. (US) 1999-09-02 — — WO disclosed
US-5280025-A Aralkylaminopyrimidine derivative, and chemical for controlling noxious organisms containing the same UBE INDUSTRIES, LTD. (JP) 1994-01-18 — — US disclosed
EP-0543402-A1 Aralkylaminopyrimidine derivative, method for preparing the same and chemical for controlling noxious organisms containing the same UBE INDUSTRIES, LTD. (JP) 1993-05-26 — — EP disclosed
US-4107326-A ANTIHYPERTENSIVE AGENTS, DIURETICS AMERICAN CYANAMID COMPANY (US) 1978-08-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12252495-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 ADRB2 1451/4885OPRM1 3051/4885OPRD1 3337/4885
US-20220220116-A1 PROTEIN KINASE B INHIBITORS PRKAR2B, PRKCB, AKT1 ADRB2 1451/4885OPRM1 3051/4885OPRD1 3337/4885
US-20030105098-A1 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines CDK6, CDK5, CDK2 ADRB2 4364/4885OPRM1 4161/4885OPRD1 3838/4885
US-20240109902-A1 PROTEIN KINASE B INHIBITORS PRKAR2B, PRKCB, AKT1 ADRB2 1451/4885OPRM1 3051/4885OPRD1 3337/4885
US-11236095-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 ADRB2 1451/4885OPRM1 3051/4885OPRD1 3337/4885
US-11760760-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 ADRB2 1451/4885OPRM1 3051/4885OPRD1 3337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.